Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Spruce Biosciences, Inc. (SPRB)
USD45.44
-0.92 (-1.98%)
US NASDAQ Healthcare Biotechnology
Address
2001 Junipero Serra Boulevard 94014
Daly City, CA, US
Daly City, CA, US
CEO
Javier Szwarcberg
Website
sprucebiosciences.com
IPO
2020-10-09
CIK 1683553 ISIN US85209E2081
Description
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD45.44
-0.92 (-1.98%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
76.7K
Beta
3.20
Float Shares
908.8K
Free Float %
66.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.47% | -1.45% | -12.16% | -14.52% | -49.66% | -34.95% | +1,044.75% | -65.34% | -94.83% | -95.56% | -95.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
45.44
Low
140.00
+208.1%
Consensus
211.50
+365.4%
Median
211.50
+365.4%
High
283.00
+522.8%
DCF (Unlevered)
61.81
+36.0%
DCF (Levered)
62.84
+38.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
140.00
+208.1%
|
| Last Quarter | 1 |
140.00
+208.1%
|
| Last Year | 5 |
219.20
+382.4%
|
| All Time | 5 |
219.20
+382.4%
|
Quality scores
Altman Z-Score
-4.62
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+47.5% ★ Q1'26: +62.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%—
-
Share dilution Biotechnology: -3.4%+42.9% Q1'26: +140.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
10.09M
est: 10.13M (-0.4%)
|
4.91M
est: 5.09M (-3.6%)
|
—
est: 2.00M (-100.0%)
|
53.75M
12.09M – 124.43M
+2,587.6% YoY
|
76.56M
41.46M – 113.51M
+42.4% YoY
|
24.23M
5.45M – 56.09M
-68.4% YoY
|
52.35M
11.77M – 121.18M
+116.0% YoY
|
88.60M
19.92M – 205.10M
+69.3% YoY
|
| EBITDA |
-47.37M
est: 2.03M (-2,438.6%)
|
-52.68M
est: 1.02M (-5,271.7%)
|
-36.51M
est: 400.0K (-9,228.3%)
|
10.75M
2.42M – 24.89M
+2,587.6% YoY
|
15.31M
8.29M – 22.70M
+42.4% YoY
|
4.85M
1.09M – 11.22M
-68.4% YoY
|
10.47M
2.35M – 24.24M
+116.0% YoY
|
17.72M
3.98M – 41.02M
+69.3% YoY
|
| EBIT |
-47.44M
est: 2.03M (-2,442.1%)
|
-52.73M
est: 1.02M (-5,276.2%)
|
-36.51M
est: 400.0K (-9,228.3%)
|
10.75M
2.42M – 24.89M
+2,587.6% YoY
|
15.31M
8.29M – 22.70M
+42.4% YoY
|
4.85M
1.09M – 11.22M
-68.4% YoY
|
10.47M
2.35M – 24.24M
+116.0% YoY
|
17.72M
3.98M – 41.02M
+69.3% YoY
|
| Net Income |
-47.92M
est: -1.44M (-3,218.0%)
|
-53.04M
est: -55.45M (+4.4%)
|
-38.97M
est: -38.97M (+0.0%)
|
-24.95M
-26.27M – -23.63M
+36.0% YoY
|
-14.30M
-14.41M – -14.19M
+42.7% YoY
|
-7.62M
-11.03M – -4.21M
+46.7% YoY
|
-877.8K
-2.38M – 6.8K
+88.5% YoY
|
9.03M
-69.5K – 24.47M
+1,128.8% YoY
|
| SGA |
12.65M
est: 14.66M (-13.7%)
|
14.64M
est: 7.37M (+98.7%)
|
16.99M
est: 2.89M (+487.1%)
|
77.79M
17.49M – 180.07M
+2,587.6% YoY
|
110.79M
60.00M – 164.26M
+42.4% YoY
|
35.06M
7.88M – 81.17M
-68.4% YoY
|
75.75M
17.03M – 175.36M
+116.0% YoY
|
128.22M
28.83M – 296.81M
+69.3% YoY
|
| EPS |
-93.00
est: -1.15 (-8,017.7%)
|
-96.75
est: -70.05 (-38.1%)
|
-50.83
est: -21.24 (-139.3%)
|
-32.54
-34.26 – -30.82
-53.2% YoY
|
-18.65
-18.79 – -18.51
+42.7% YoY
|
-9.94
-14.39 – -5.49
+46.7% YoY
|
-1.15
-3.10 – 0.01
+88.5% YoY
|
11.78
-0.09 – 31.92
+1,128.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-35.79M
OE per share TTM
-58.79
Owner's Yield
-82.78%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
50.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
5
Total invested
2.79M
Insider transactions (90d)
0
Beneficial owners (>5%)
36
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 5AM Opportunities II (GP), LLC | 4.14M | 9.97% | — | 4.14M | — | — | OO | United States | 2023-02-27 | ↗ |
| 2 | 5AM Opportunities II, L.P. | 4.14M | 9.97% | — | 4.14M | — | — | PN | United States | 2023-02-27 | ↗ |
| 3 | Andrew J. Schwab | 4.14M | 9.97% | — | 4.14M | — | — | IN | United States | 2023-02-27 | ↗ |
| 4 | Dr. Kush Parmar | 4.14M | 9.97% | — | 4.14M | — | — | IN | United States | 2023-02-27 | ↗ |
| 5 | Bradley L. Radoff | 2.83M | 6.90% | — | — | 2.83M | — | IN | USA | 2024-03-28 | ↗ |
| 6 | Armistice Capital, LLC | 2.23M | 5.48% | — | 2.23M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 7 | Steven Boyd | 2.23M | 5.48% | — | 2.23M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 8 | Anne-Mari Paster | 2.16M | 9.30% | — | 2.16M | — | 2.16M | IN | — | 2021-02-12 | ↗ |
| 9 | Claudio Nessi | 2.16M | 9.30% | — | 2.16M | — | 2.16M | IN | — | 2021-02-12 | ↗ |
| 10 | Omega Fund VI GP Manager, Ltd. | 2.16M | 9.30% | — | 2.16M | — | 2.16M | OO | — | 2021-02-12 | ↗ |
| 11 | Omega Fund VI GP, L.P. | 2.16M | 9.30% | — | 2.16M | — | 2.16M | PN | — | 2021-02-12 | ↗ |
| 12 | Omega Fund VI, L.P. | 2.16M | 9.30% | — | 2.16M | — | 2.16M | PN | — | 2021-02-12 | ↗ |
| 13 | Otello Stampacchia | 2.16M | 9.30% | — | 2.16M | — | 2.16M | IN | — | 2021-02-12 | ↗ |
| 14 | Rock Springs Capital LLC | 1.62M | 6.92% | — | 1.62M | — | — | HC, OO | Delaware | 2022-02-15 | ↗ |
| 15 | Rock Springs Capital Management LP | 1.62M | 6.92% | — | 1.62M | — | — | IA | Delaware | 2022-02-15 | ↗ |
| 16 | Rock Springs Capital Master Fund LP | 1.53M | 6.50% | — | 1.53M | — | — | PN | Cayman Islands | 2022-02-15 | ↗ |
| 17 | Company, L.P. | 1.42M | 6.09% | — | 1.42M | — | — | PN | Delaware | 2021-05-17 | ↗ |
| 18 | Deerfield Mgmt, L.P. | 1.42M | 6.09% | — | 1.42M | — | — | PN | Delaware | 2021-05-17 | ↗ |
| 19 | Deerfield Partners, L.P. | 1.42M | 6.09% | — | 1.42M | — | — | PN | Delaware | 2021-05-17 | ↗ |
| 20 | James E. Flynn | 1.42M | 6.09% | — | 1.42M | — | — | IN | Delaware | 2021-05-17 | ↗ |
| 21 | Aisling Capital Partners V LLC | 1.21M | 5.18% | — | 1.21M | — | 1.21M | OO | — | 2021-02-12 | ↗ |
| 22 | Aisling Capital Partners V, LP | 1.21M | 5.18% | — | 1.21M | — | 1.21M | PN | — | 2021-02-12 | ↗ |
| 23 | Aisling Capital V, LP | 1.21M | 5.18% | 1.21M | — | 1.21M | — | PN | — | 2021-02-12 | ↗ |
| 24 | Andrew Schiff | 1.21M | 5.18% | — | 1.21M | — | 1.21M | IN | — | 2021-02-12 | ↗ |
| 25 | Steve Elms | 1.21M | 5.18% | — | 1.21M | — | 1.21M | IN | — | 2021-02-12 | ↗ |
| 26 | Abigail P. Johnson | 1.19M | 5.14% | 205.5K | — | 1.19M | — | IN | Delaware | 2021-02-08 | ↗ |
| 27 | Citadel Advisors Holdings LP | 10.00 | 7.30% | — | 1.70M | — | — | HC, PN | Delaware | 2021-02-16 | ↗ |
| 28 | Citadel GP LLC | 10.00 | 7.30% | — | 1.70M | — | — | HC, OO | Delaware | 2021-02-16 | ↗ |
| 29 | Kenneth Griffin | 10.00 | 7.30% | — | 1.70M | — | — | HC, IN | Delaware | 2021-02-16 | ↗ |
| 30 | 2. | 10.00 | 7.20% | — | 1.70M | — | — | IA, HC, OO | — | 2022-02-14 | ↗ |
| 31 | CALC IV LP | 10.00 | 0.00% | — | — | — | — | HC, PN | Delaware | 2021-02-16 | ↗ |
| 32 | Citadel Securities GP LLC | 10.00 | 0.00% | — | — | — | — | HC, OO | Delaware | 2021-02-16 | ↗ |
| 33 | Citadel Securities LLC | 10.00 | 0.00% | — | — | — | — | BD, OO | Delaware | 2021-02-16 | ↗ |
| 34 | Gil Aharon | — | 0.00% | — | — | — | — | PN | ONTARIO, CANADA | 2024-10-23 | ↗ |
| 35 | Rosalind Master Fund L.P. | — | 0.00% | — | — | — | — | PN | ONTARIO, CANADA | 2024-10-23 | ↗ |
| 36 | Steven Salamon | — | 0.00% | — | — | — | — | IN | ONTARIO, CANADA | 2024-10-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
5
-27 vs prev Q
New positions
1
Closed positions
28
Increased
1
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | IKARIAN CAPITAL, LLC | 121.4K +108.0K (+810.3%) | 10.57M +10.5M (+8,759.5%) | 21.55% +19.185 pp | 0.83% +0.813 pp | USD78.52 +10.9% | 2 qtrs — |
| 2 | — | 70.0K +70.0K (+100.0%) | 6.10M +6.1M (+100.0%) | 12.43% +12.432 pp | 2.58% +2.584 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 3 | CITADEL ADVISORS LLC | 70.0K +70.0K (+100.0%) | 6.10M +6.1M (+100.0%) | 12.43% +12.432 pp | 0.00% +0.001 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 58.9K +58.9K (+100.0%) | 5.14M +5.1M (+100.0%) | 10.47% +10.469 pp | 0.00% +0.001 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 5 | ADAR1 CAPITAL MANAGEMENT, LLC | 58.0K +58.0K (+100.0%) | 5.05M +5.1M (+100.0%) | 10.30% +10.301 pp | 0.37% +0.371 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 6 | ALYESKA INVESTMENT GROUP, L.P. | 51.7K +51.7K (+100.0%) | 4.50M +4.5M (+100.0%) | 9.18% +9.177 pp | 0.01% +0.013 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 7 | BOOTHBAY FUND MANAGEMENT, LLC | 47.9K +47.9K (+100.0%) | 4.18M +4.2M (+100.0%) | 8.51% +8.513 pp | 0.06% +0.062 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 8 | BALYASNY ASSET MANAGEMENT L.P. | 40.0K +40.0K (+100.0%) | 3.48M +3.5M (+100.0%) | 7.10% +7.104 pp | 0.00% +0.004 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 9 | CARLYLE GROUP INC. | 38.6K -2.9M (-98.7%) | 3.30M -21.5M (-86.7%) | 6.86% -507.560 pp | 0.02% -0.547 pp | USD8.95 +873.3% | 2 qtrs — |
| 10 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 25.3K +25.3K (+100.0%) | 2.20M +2.2M (+100.0%) | 4.49% +4.488 pp | 0.02% +0.017 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 11 | SCHONFELD STRATEGIC ADVISORS LLC | 24.8K +24.8K (+100.0%) | 2.16M +2.2M (+100.0%) | 4.40% +4.399 pp | 0.01% +0.010 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 12 | QUINN OPPORTUNITY PARTNERS LLC | 22.8K +22.8K (+100.0%) | 1.99M +2.0M (+100.0%) | 4.05% +4.051 pp | 0.08% +0.084 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 13 | CALIGAN PARTNERS LP | 20.5K +20.5K (+100.0%) | 1.79M +1.8M (+100.0%) | 3.64% +3.643 pp | 0.15% +0.147 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 14 | STONEPINE CAPITAL MANAGEMENT, LLC | 19.7K +19.7K (+100.0%) | 1.72M +1.7M (+100.0%) | 3.51% +3.506 pp | 1.26% +1.256 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 15 | VANGUARD GROUP INC | 17.9K +17.9K (+100.0%) | 1.56M +1.6M (+100.0%) | 3.17% +3.174 pp | 0.00% +0.000 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 16 | BLACKROCK, INC. | 16.9K +16.9K (+100.0%) | 1.48M +1.5M (+100.0%) | 3.01% +3.008 pp | 0.00% +0.000 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 12.7K +12.7K (+100.0%) | 1.11M +1.1M (+100.0%) | 2.26% +2.261 pp | 0.00% +0.000 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 18 | SUPERSTRING CAPITAL MANAGEMENT LP | 12.1K +12.1K (+100.0%) | 1.06M +1.1M (+100.0%) | 2.16% +2.156 pp | 0.57% +0.566 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 19 | STATE STREET CORP | 6.4K +6.4K (+100.0%) | 557.5K +557.5K (+100.0%) | 1.14% +1.137 pp | 0.00% +0.000 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 20 | UBS GROUP AG | 4.9K +4.8K (+3,613.6%) | 427.0K +425.8K (+36,056.9%) | 0.87% +0.847 pp | 0.00% +0.000 pp | USD85.01 +2.5% | 2 qtrs — |
| 21 | RESOLUTE CAPITAL ASSET PARTNERS LLC | 4.0K +4.0K (+100.0%) | 348.4K +348.4K (+100.0%) | 0.71% +0.710 pp | 0.17% +0.168 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 22 | SKYVIEW INVESTMENT ADVISORS, LLC | 3.0K +3.0K (+100.0%) | 261.0K +261.0K (+100.0%) | 0.53% +0.533 pp | 0.03% +0.033 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 23 | NORTHERN TRUST CORP | 2.4K +2.4K (+100.0%) | 211.0K +211.0K (+100.0%) | 0.43% +0.430 pp | 0.00% +0.000 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 24 | BNP PARIBAS ARBITRAGE, SNC | 2.0K +2.0K (+100.0%) | 174.2K +174.2K (+100.0%) | 0.36% +0.355 pp | 0.00% +0.000 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 25 | LION POINT CAPITAL, LP | 1.0K +— (+0.0%) | 87.1K +78.2K (+873.3%) | 0.18% +0.000 pp | 0.45% +0.400 pp | USD8.95 +873.3% | 2 qtrs — |
| 26 | MORGAN STANLEY | 388.00 +290.0 (+295.9%) | 33.8K +32.9K (+3,749.5%) | 0.07% +0.052 pp | 0.00% +0.000 pp | USD67.37 +29.3% | 2 qtrs — |
| 27 | SOUND INCOME STRATEGIES, LLC | 200.00 +200.0 (+100.0%) | 14.7K +14.7K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.001 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 28 | BANK OF AMERICA CORP /DE/ | 93.00 +90.0 (+3,000.0%) | 8.1K +8.1K (+29,903.7%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD84.57 +3.0% | 2 qtrs — |
| 29 | JONES FINANCIAL COMPANIES LLLP | 84.00 +84.0 (+100.0%) | 7.3K +7.3K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.000 pp | USD87.11 +0.0% | 1 qtrs NEW |
| 30 | ROYAL BANK OF CANADA | 40.00 +40.0 (+100.0%) | 3.0K +3.0K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD87.10 +0.0% | 1 qtrs NEW |
| 31 | CALDWELL SUTTER CAPITAL, INC. | 13.00 +— (+0.0%) | 1.1K +1.0K (+875.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.92 +876.6% | 2 qtrs — |
| 32 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.00 +1.0 (+100.0%) | 87.00 +87.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD87.00 +0.1% | 1 qtrs NEW |
| 33 | CABLE CAR CAPITAL LLC | — -26.7K (-100.0%) | — -238.7K (-100.0%) | 0.00% -4.736 pp | 0.00% -0.102 pp | USD— | 2 qtrs SOLD |
| 34 | ADVISOR GROUP HOLDINGS, INC. | — -133.0 (-100.0%) | — -931.0 (-100.0%) | 0.00% -0.024 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 39 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.49% | 107.2K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.03% | 456.7K | 0.60% |
| 3 | iShares Russell 2000 Value ETF IWN | 0.01% | 878.1K | 0.24% |
| 4 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 137.9K | 0.30% |
| 5 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 13.8K | 0.25% |
| 6 | Global X - Russell 2000 ETF RSSL | 0.00% | 63.7K | 0.08% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 2.4K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 3.51M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 22.9K | 0.36% |
| 10 | iShares Russell 2000 Growth ETF IWO | 0.00% | 327.8K | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
11.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+11,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | Hooks Corwin Dale | Officer | A-Award | A | Restricted Stock Units | 11,000 | 0.00 | — | 11,000 | D | ↗ |
| 2025-12-31 | Szwarcberg Javier B. | Director / Officer | A-Award | A | Common Stock | 4,690 | 4.53 | 21.2K | 19,004 | D | ↗ |
| 2025-12-15 | Szwarcberg Javier B. | Director / Officer | M-Exempt | D | Restricted Stock Units | 1,480 | 0.00 | — | 1,480 | D | ↗ |
| 2025-12-15 | Gharib Samir M. | Officer | M-Exempt | A | Common Stock | 496 | 0.00 | — | 8,112 | D | ↗ |
| 2025-12-11 | Ways Douglas Kirk | Director / Officer | A-Award | A | Restricted Stock Units | 5,000 | 0.00 | — | 5,000 | D | ↗ |
| 2025-12-11 | Walbert Keli | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-11 | Szwarcberg Javier B. | Director / Officer | D-Return | D | Employee Stock Option (right to buy) | 10,000 | 344.25 | 3.44M | 0 | D | ↗ |
| 2025-12-11 | SPIEGELMAN DANIEL K | Director | D-Return | D | Stock Option (Right to Buy) | 458 | 564.00 | 258.3K | 0 | D | ↗ |
| 2025-12-11 | SIMPSON CAMILLA V | Director | D-Return | D | Stock Option (Right to Buy) | 400 | 169.50 | 67.8K | 0 | D | ↗ |
| 2025-12-11 | Gharib Samir M. | Officer | D-Return | D | Stock Option (Right to Buy) | 733 | 1,506.00 | 1.10M | 0 | D | ↗ |
| 2025-12-11 | GREY MICHAEL G | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,499 | 104.13 | 156.1K | 1,499 | D | ↗ |
| 2025-12-11 | Barretto-Ko Percival | Director | A-Award | A | Stock Option (Right to Buy) | 800 | 104.13 | 83.3K | 800 | D | ↗ |
| 2025-12-10 | Szwarcberg Javier B. | Director / Officer | M-Exempt | A | Common Stock | 1,196 | 0.00 | — | 10,670 | D | ↗ |
| 2025-12-10 | Gharib Samir M. | Officer | M-Exempt | A | Common Stock | 514 | 0.00 | — | 6,580 | D | ↗ |
| 2025-10-20 | Szwarcberg Javier B. | Director / Officer | M-Exempt | A | Common Stock | 4,784 | 0.00 | — | 11,013 | D | ↗ |
| 2025-10-20 | Gharib Samir M. | Officer | F-InKind | D | Common Stock | 661 | 148.16 | 97.9K | 6,066 | D | ↗ |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value per share | 256 | 17.91 | 4.6K | 1,307 | I | ↗ |
| 2025-07-23 | Ways Kirk | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.12 | 3.7K | 30,000 | D | ↗ |
| 2025-07-22 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.12 | 3.5K | 30,000 | D | ↗ |
| 2025-07-22 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.12 | 3.5K | 30,000 | D | ↗ |
| 2025-07-22 | Muralidhar Bali | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.12 | 3.5K | 30,000 | D | ↗ |
| 2025-07-22 | GREY MICHAEL G | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.12 | 3.5K | 30,000 | D | ↗ |
| 2025-07-22 | Barretto-Ko Percival | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.12 | 3.5K | 30,000 | D | ↗ |
| 2025-07-22 | Aynechi Tiba | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.12 | 3.5K | 30,000 | D | ↗ |
| 2024-12-16 | Szwarcberg Javier B. | Director / Officer | F-InKind | D | Common Stock | 39,605 | 0.39 | 15.4K | 467,191 | D | ↗ |
| 2024-12-16 | Gharib Samir M. | Officer | F-InKind | D | Common Stock | 13,737 | 0.39 | 5.3K | 326,591 | D | ↗ |
| 2024-12-16 | Charlton Ralph William III | Officer | M-Exempt | A | Common Stock | 31,750 | 0.00 | — | 172,668 | D | ↗ |
| 2024-12-10 | Szwarcberg Javier B. | Director / Officer | F-InKind | D | Common Stock | 128,020 | 0.54 | 68.7K | 338,101 | D | ↗ |
| 2024-12-10 | Gharib Samir M. | Officer | M-Exempt | A | Common Stock | 154,000 | 0.00 | — | 356,776 | D | ↗ |
| 2024-12-10 | Charlton Ralph William III | Officer | M-Exempt | A | Common Stock | 106,400 | 0.00 | — | 161,773 | D | ↗ |
| 2024-05-22 | Ways Kirk | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.75 | 22.5K | 30,000 | — | ↗ |
| 2024-05-22 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.75 | 22.5K | 30,000 | — | ↗ |
| 2024-05-22 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.75 | 22.5K | 30,000 | — | ↗ |
| 2024-05-22 | Muralidhar Bali | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.75 | 22.5K | 30,000 | — | ↗ |
| 2024-05-22 | GREY MICHAEL G | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.75 | 22.5K | 30,000 | — | ↗ |
| 2024-05-22 | Barretto-Ko Percival | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.75 | 22.5K | 30,000 | — | ↗ |
| 2024-05-22 | Aynechi Tiba | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.75 | 22.5K | 30,000 | — | ↗ |
| 2024-03-21 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 465,021 | 0.75 | 351.0K | 2,550,000 | — | ↗ |
| 2024-03-20 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 359,979 | 0.73 | 264.1K | 3,015,021 | — | ↗ |
| 2024-03-19 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 593,000 | 0.76 | 447.7K | 3,375,000 | — | ↗ |
| 2024-03-18 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 842,020 | 0.77 | 647.0K | 3,968,000 | — | ↗ |
| 2024-03-14 | Szwarcberg Javier B. | Director / Officer | A-Award | A | Restricted Stock Units | 358,800 | 0.00 | — | 358,800 | — | ↗ |
| 2024-03-14 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 1,912,316 | 0.89 | 1.70M | 4,810,020 | — | ↗ |
| 2024-03-14 | Gharib Samir M. | Officer | A-Award | A | Restricted Stock Units | 154,000 | 0.00 | — | 154,000 | — | ↗ |
| 2024-03-14 | Charlton Ralph William III | Officer | A-Award | A | Restricted Stock Units | 106,400 | 0.00 | — | 106,400 | — | ↗ |
| 2023-12-29 | Gharib Samir M. | Officer | A-Award | A | Common Stock | 11,255 | 0.98 | 11.0K | 202,776 | — | ↗ |
| 2023-12-29 | Charlton Ralph William III | Officer | A-Award | A | Common Stock | 9,361 | 0.98 | 9.2K | 55,373 | — | ↗ |
| 2023-12-15 | Szwarcberg Javier B. | Director / Officer | M-Exempt | D | Restricted Stock Units | 111,000 | 0.00 | — | 333,000 | — | ↗ |
| 2023-12-15 | Gharib Samir M. | Officer | M-Exempt | D | Restricted Stock Units | 37,250 | 0.00 | — | 111,750 | — | ↗ |
| 2023-12-15 | Charlton Ralph William III | Officer | F-InKind | D | Common Stock | 10,980 | 1.66 | 18.2K | 46,012 | — | ↗ |
| 2023-12-14 | Szwarcberg Javier B. | Director / Officer | A-Award | A | Restricted Stock Units | 717,600 | 0.00 | — | 717,600 | — | ↗ |
| 2023-12-14 | Gharib Samir M. | Officer | A-Award | A | Restricted Stock Units | 308,000 | 0.00 | — | 308,000 | — | ↗ |
| 2023-12-14 | Charlton Ralph William III | Officer | A-Award | A | Restricted Stock Units | 212,800 | 0.00 | — | 212,800 | — | ↗ |
| 2023-11-26 | Szwarcberg Javier B. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 4.59 | 573.8K | 125,000 | — | ↗ |
| 2023-11-08 | Gharib Samir M. | Officer | A-Award | A | Restricted Stock Units | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-06-30 | Szwarcberg Javier B. | Director / Officer | A-Award | A | Common Stock | 20,000 | 0.98 | 19.6K | 34,705 | — | ↗ |
| 2023-06-30 | Gharib Samir M. | Officer | M-Exempt | D | Restricted Stock Units | 75,000 | 0.00 | — | 150,000 | — | ↗ |
| 2023-06-30 | Charlton Ralph William III | Officer | A-Award | A | Common Stock | 12,378 | 0.98 | 12.1K | 25,242 | — | ↗ |
| 2023-05-25 | Ways Kirk | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.26 | 67.8K | 30,000 | — | ↗ |
| 2023-05-25 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.26 | 67.8K | 30,000 | — | ↗ |
| 2023-05-25 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.26 | 67.8K | 30,000 | — | ↗ |
| 2023-05-25 | O'Donnell Niall | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.26 | 67.8K | 30,000 | — | ↗ |
| 2023-05-25 | Muralidhar Bali | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.26 | 67.8K | 30,000 | — | ↗ |
| 2023-05-25 | GREY MICHAEL G | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.26 | 67.8K | 30,000 | — | ↗ |
| 2023-05-25 | Barretto-Ko Percival | Director | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-25 | Aynechi Tiba | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.26 | 67.8K | 30,000 | — | ↗ |
| 2023-02-16 | O'Donnell Niall | Director | P-Purchase | A | Common Stock | 630,400 | 3.17 | 2.00M | 1,326,305 | — | ↗ |
| 2023-02-16 | Novo Holdings A/S | 10% Owner | P-Purchase | A | COMMON STOCK | 2,208,000 | 3.17 | 7.00M | 6,722,336 | — | ↗ |
| 2023-01-03 | Gharib Samir M. | Officer | M-Exempt | A | Common Stock | 37,500 | 0.00 | — | 71,111 | — | ↗ |
| 2022-12-30 | Szwarcberg Javier B. | Officer | A-Award | A | Common Stock | 14,705 | 0.93 | 13.7K | 14,705 | — | ↗ |
| 2022-12-30 | Gharib Samir M. | Officer | A-Award | A | Common Stock | 1 | 0.93 | 0.93 | 33,611 | — | ↗ |
| 2022-12-30 | Charlton Ralph William III | Officer | A-Award | A | Common Stock | 12,864 | 0.93 | 12.0K | 12,864 | — | ↗ |
| 2022-12-05 | Szwarcberg Javier B. | Officer | A-Award | A | Restricted Stock Units | 444,000 | 0.00 | — | 444,000 | — | ↗ |
| 2022-12-05 | Gharib Samir M. | Officer | A-Award | A | Restricted Stock Units | 149,000 | 0.00 | — | 149,000 | — | ↗ |
| 2022-12-05 | Charlton Ralph William III | Officer | A-Award | A | Restricted Stock Units | 127,000 | 0.00 | — | 127,000 | — | ↗ |
| 2022-06-30 | Gharib Samir M. | Officer | A-Award | A | Common Stock | 5,446 | 1.48 | 8.1K | 46,578 | — | ↗ |
| 2022-05-25 | Ways Kirk | Director | A-Award | A | Stock Option (Right to Buy) | 20,625 | 0.00 | — | 20,625 | — | ↗ |
| 2022-05-25 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 1.32 | 29.7K | 22,500 | — | ↗ |
| 2022-05-25 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-25 | O'Donnell Niall | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-25 | Muralidhar Bali | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 1.32 | 29.7K | 22,500 | — | ↗ |
| 2022-05-25 | GREY MICHAEL G | Officer | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-25 | Chaya Moghrabi Dina | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-25 | Aynechi Tiba | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-04-01 | Charlton Ralph William III | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-03-28 | Charlton Ralph William III | Officer | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-03 | Szwarcberg Javier B. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 4.59 | 3.44M | 750,000 | — | ↗ |
| 2022-01-03 | Gharib Samir M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 70,000 | 4.59 | 321.3K | 70,000 | — | ↗ |
| 2022-01-01 | Szwarcberg Javier B. | Director / Officer | — | D | Employee Stock Option (right to buy) | 250,000 | 4.59 | 1.15M | 0 | — | ↗ |
| 2021-12-31 | Gharib Samir M. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-16 | Gharib Samir M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 145,000 | 2.48 | 359.6K | 145,000 | — | ↗ |
| 2021-12-16 | GREY MICHAEL G | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 2.48 | 124.0K | 50,000 | — | ↗ |
| 2021-12-16 | Dias Subaweerage | Officer | A-Award | A | Restricted Stock Units | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2021-06-30 | KING RICHARD | Director / Officer | J-Other | A | Common Stock | 2,230 | 9.53 | 21.2K | 2,230 | — | ↗ |
| 2021-06-30 | Gharib Samir M. | Officer | J-Other | A | Common Stock | 1,412 | 9.53 | 13.5K | 1,412 | — | ↗ |
| 2021-06-23 | Ways Kirk | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 10.55 | 211.0K | 20,000 | — | ↗ |
| 2021-05-20 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 6,667 | 15.24 | 101.6K | 6,667 | — | ↗ |
| 2021-05-20 | SIMPSON CAMILLA V | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 15.24 | 152.4K | 10,000 | — | ↗ |
| 2021-05-20 | O'Donnell Niall | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 15.24 | 152.4K | 10,000 | — | ↗ |
| 2021-05-20 | Muralidhar Bali | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 15.24 | 152.4K | 10,000 | — | ↗ |
| 2021-05-20 | GREY MICHAEL G | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 15.24 | 152.4K | 10,000 | — | ↗ |
| 2021-05-20 | Chaya Moghrabi Dina | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 15.24 | 152.4K | 10,000 | — | ↗ |
| 2021-05-19 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 475,000 | 13.90 | 6.60M | 4,514,336 | — | ↗ |
| 2021-04-30 | SIMPSON CAMILLA V | Director | M-Exempt | A | Common Stock | 14,045 | 0.85 | 11.9K | 14,045 | — | ↗ |
| 2021-01-28 | KING RICHARD | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 155,000 | 20.08 | 3.11M | 155,000 | — | ↗ |
| 2021-01-28 | Gharib Samir M. | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 20.08 | 1.10M | 55,000 | — | ↗ |
| 2021-01-28 | Dias Subaweerage | Officer | A-Award | A | Stock Option (Right to Buy) | 27,500 | 20.08 | 552.2K | 27,500 | — | ↗ |
| 2020-10-14 | RiverVest Venture Fund III, L.P. | 10% Owner | C-Conversion | A | Common Stock | 828,109 | 0.00 | — | 1,898,281 | — | ↗ |
| 2020-10-14 | Omega Fund VI, L.P. | — | C-Conversion | D | Series B Preferred Stock | 12,500,000 | 0.00 | — | 0 | — | ↗ |
| 2020-10-14 | O'Donnell Niall | Director | C-Conversion | D | Series B Preferred Stock | 2,916,664 | 0.00 | — | 0 | — | ↗ |
| 2020-10-14 | Novo Holdings A/S | 10% Owner | C-Conversion | A | COMMON STOCK | 4,739,336 | 0.00 | — | 4,739,336 | — | ↗ |
| 2020-10-14 | Muralidhar Bali | Director | C-Conversion | D | Series B Preferred Stock | 10,416,666 | 0.00 | — | 0 | — | ↗ |
| 2020-10-14 | HealthCap VIII, L.P. | — | C-Conversion | A | Common Stock | 1,783,621 | 0.00 | — | 1,783,621 | — | ↗ |
| 2020-10-14 | HANSSON JONAS | Director | C-Conversion | D | Series B Preferred Stock | 11,666,666 | 0.00 | — | 0 | — | ↗ |
| 2020-10-14 | Chaya Moghrabi Dina | Director | P-Purchase | A | Common Stock | 250,000 | 15.00 | 3.75M | 2,161,022 | — | ↗ |
| 2020-10-08 | SPIEGELMAN DANIEL K | Director | — | D | Stock Option (Right to Buy) | 34,398 | 7.52 | 258.7K | 0 | — | ↗ |
| 2020-10-08 | SIMPSON CAMILLA V | Director | — | D | Stock Option (Right to Buy) | 27,212 | 3.07 | 83.5K | 0 | — | ↗ |
| 2020-10-08 | RiverVest Venture Fund III, L.P. | 10% Owner | — | I | Series A Preferred Stock | 1,070,172 | 0.00 | — | 0 | — | ↗ |
| 2020-10-08 | O'Donnell Niall | Director | — | I | Series B Preferred Stock | 445,905 | 0.00 | — | 0 | — | ↗ |
| 2020-10-08 | Novo Holdings A/S | 10% Owner | — | D | SERIES B CONVERTIBLE PREFERRED STOCK | 1,528,818 | 0.00 | — | 0 | — | ↗ |
| 2020-10-08 | Muralidhar Bali | Director | — | I | Series B Preferred Stock | 1,592,518 | 0.00 | — | 0 | — | ↗ |
| 2020-10-08 | KING RICHARD | Director / Officer | — | D | Stock Option (Right to Buy) | 310,197 | 3.07 | 952.3K | 0 | — | ↗ |
| 2020-10-08 | HealthCap VIII, L.P. | 10% Owner | — | D | Series B Preferred Stock | 1,783,621 | 0.00 | — | 0 | — | ↗ |
| 2020-10-08 | HANSSON JONAS | Director | — | I | Series B Preferred Stock | 1,783,621 | 0.00 | — | 0 | — | ↗ |
| 2020-10-08 | Gharib Samir M. | Officer | — | D | Stock Option (Right to Buy) | 118,483 | 1.64 | 194.3K | 0 | — | ↗ |
| 2020-10-08 | GREY MICHAEL G | Director / Officer | — | D | Stock Option (Right to Buy) | 94,174 | 1.64 | 154.4K | 0 | — | ↗ |
| 2020-10-08 | Dias Subaweerage | Officer | — | D | Stock Option (Right to Buy) | 209,035 | 7.52 | 1.57M | 0 | — | ↗ |
| 2020-10-08 | Chaya Moghrabi Dina | Director | — | I | Series B Preferred Stock | 1,911,022 | 0.00 | — | 0 | — | ↗ |
| 2020-10-08 | Aynechi Tiba | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.37M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Javier Szwarcberg, M.D., MPH Chief Executive Officer | 610.0K | 503.3K | 1.75M | 41.8K | — | 5.0K | 2.91M | 61.58% | ↗ |
| 2 | 2025 | Samir Gharib President and Chief Financial Officer | 465.1K | 313.9K | 671.9K | 17.3K | — | 5.0K | 1.47M | 46.78% | ↗ |
| 3 | 2025 | Kirk Ways, M.D., Ph.D. Interim Chief Medical Officer | — | — | 442.1K | 5.5K | — | 596.8K | 1.04M | 42.85% | ↗ |
| 4 | 2024 | Javier Szwarcberg, M.D., MPH Chief Executive Officer | 610.0K | 335.5K | 581.7K | — | — | 5.0K | 1.53M | 37.96% | ↗ |
| 5 | 2024 | Ralph William Charlton III, M.D., M.A.S. Former Chief Medical Officer | 457.6K | 183.0K | 172.5K | — | — | 348.2K | 1.16M | 14.85% | ↗ |
| 6 | 2024 | Samir Gharib President and Chief Financial Officer | 465.1K | 209.9K | 249.7K | — | — | 5.0K | 929.7K | 26.85% | ↗ |
| 7 | 2023 | Javier Szwarcberg, M.D., MPH Chief Executive Officer | 580.0K | 47.9K | 1.21M | — | 319.0K | 5.0K | 2.16M | 55.88% | ↗ |
| 8 | 2023 | Samir Gharib President and Chief Financial Officer | 447.2K | 30.2K | 517.4K | — | 201.2K | 5.0K | 1.20M | 43.08% | ↗ |
| 9 | 2023 | Ralph William Charlton III, M.D., M.A.S. Chief Medical Officer | 440.0K | 26.4K | 357.5K | — | 176.0K | 5.0K | 1.00M | 35.58% | ↗ |
| 10 | 2023 | Ralph William Charlton III, M.D., M.A.S. Former Chief Medical Officer | 440.0K | 26.4K | 357.5K | — | 176.0K | 5.0K | 1.00M | 35.58% | ↗ |
| 11 | 2022 | Javier Szwarcberg, M.D., MPH Chief Executive Officer | 540.0K | — | 519.5K | 3.27M | 153.9K | 5.0K | 4.49M | 84.44% | ↗ |
| 12 | 2022 | Samir Gharib President and Chief Financial Officer | 425.8K | — | 174.3K | 259.9K | 110.3K | 5.0K | 975.4K | 44.52% | ↗ |
| 13 | 2022 | Ralph William Charlton III, M.D., M.A.S. Chief Medical Officer | 305.6K | — | 148.6K | 433.5K | 69.7K | 5.0K | 962.4K | 60.49% | ↗ |
| 14 | 2022 | Michael Grey Executive Chairman and Former Interim Chief Executive Officer | 70.0K | — | — | 29.7K | — | — | 99.7K | 29.79% | ↗ |
| 15 | 2021 | Richard King Former Chief Executive Officer | 437.5K | — | — | 4.11M | — | 559.7K | 5.11M | 80.47% | ↗ |
| 16 | 2021 | Samir Gharib President and Chief Financial Officer | 380.0K | — | 558.0K | 1.16M | 100.0K | — | 2.19M | 78.13% | ↗ |
| 17 | 2021 | Rosh Dias, M.D., M.R.C.P. Former Chief Medical Officer | 430.0K | — | 49.6K | 583.0K | 43.0K | — | 1.11M | 57.22% | ↗ |
| 18 | 2021 | Michael Grey Executive Chairman and Former Interim Chief Executive Officer | 65.0K | — | — | 667.3K | — | — | 732.3K | 91.12% | ↗ |
| 19 | 2020 | Richard King Former Chief Executive Officer | 409.6K | — | — | 1.63M | 430.0K | — | 2.47M | 65.98% | ↗ |
| 20 | 2020 | Richard King Chief Executive Officer | 409.6K | — | — | 1.63M | 430.0K | — | 2.47M | 65.98% | ↗ |
| 21 | 2020 | Rosh Dias, M.D., M.R.C.P. Chief Medical Officer | 159.8K | — | — | 1.38M | 52.5K | 91.6K | 1.68M | 81.92% | ↗ |
| 22 | 2020 | Rosh Dias, M.D., M.R.C.P. Former Chief Medical Officer | 159.8K | — | — | 1.38M | 52.5K | 91.6K | 1.68M | 81.92% | ↗ |
| 23 | 2020 | Samir Gharib President and Chief Financial Officer | 227.4K | — | — | 452.2K | 113.9K | — | 793.4K | 56.99% | ↗ |
| 24 | 2020 | Samir Gharib Chief Financial Officer | 227.4K | — | — | 452.2K | 113.9K | — | 793.4K | 56.99% | ↗ |
| 25 | 2020 | Michael Grey Executive Chairman and Former Interim Chief Executive Officer | — | — | — | 608.0K | — | 14.9K | 622.9K | 97.62% | ↗ |
| 26 | 2019 | Richard King Chief Executive Officer | 270.5K | — | — | 229.3K | 50.0K | — | 549.8K | 41.71% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Javier Szwarcberg | Chief Executive Officer & Director | 1M | — |
| Samir Gharib | President & Chief Financial Officer | 784.0K | male |
| Kirk Ways | Chief Medical Officer & Director | 596.8K | — |
| Michael G. Grey | Executive Chairman | 70.0K | male |
| Corwin Dale Hooks | Chief Commercial Officer | — | male |
| Daven Mody | Senior Vice President of Regulatory & Quality | — | — |
| Bruno Gagnon BPHARM | Senior Vice President of Clinical Development Operations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPRB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
